UNSPSC 51372123: Hydrocodone hydrochloride

This classification denotes an opioid receptor agonist and opioid and antitussive agent with the molecular formula C18H21NO3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QKZ0920OV3. European Medicines Agency schedules hydrocodone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14131MIG. The term hydrocodone hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule hydrocodone hydrochloride under HS 29391100.

As of Q4 2014, HYDROCODONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2C(=O)CC[C@H]3[C@H]1C5)OC.CL.

UNSPSC 51372123 Hydrocodone hydrochloride is a Commodity code that nominally names a single pharmaceutical product, yet recent state and local solicitations tagged under this code span a much broader pharmaceutical procurement landscape—from naloxone and drug deactivation systems to generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. The actual buying activity reflects state health agencies, county health departments, and multistate cooperative purchasing alliances sourcing controlled substances, opioid-reversal medications, and generic pharmaceutical inventories to support public health initiatives, community health programs, and state employee and retiree pharmacy benefits. Issuing bodies include state agencies such as the Texas Health and Human Services Commission and the Minnesota Department of Administration, county health departments such as Seminole County, Florida, and multistate cooperative purchasing vehicles such as MMCAP that aggregate demand across multiple participating jurisdictions. The mismatch between the code's nominal scope (a single drug product) and the breadth of recent solicitations suggests the code is being used as a catch-all tag for pharmaceutical procurement opportunities that do not fit more specific commodity codes, or that state and local procurement systems have applied the code inconsistently across diverse pharmacy-related buys.

Recent activity appears concentrated in the Upper Midwest and Southeast, with the Minnesota Multistate Cooperative Purchasing Alliance (serving Minnesota and Oregon), Seminole County, Florida, and the Texas Health and Human Services Commission posting the most visible solicitations. Seminole County issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline, supporting quarterly deliveries to its community health building; the contract included a two-year initial term with one-year renewal options and required E-Verify compliance and drug-free workplace certification. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, released an RFP in January 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), with evaluation weighted heavily toward price competitiveness (75 percent) and a July 1, 2026 contract effective date. The Texas Health and Human Services Commission issued a preliminary RFI (HHS0017013) in April 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs, signaling early-stage market research before formal procurement. None of these opportunities explicitly specified budget ranges, set-aside designations, or incumbent contractor information in publicly available materials.